Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M
Bristol-Myers Squibb has turned to Paris-based microbiome expert Enterome for its latest immuno-oncology partnership. The biotech landed a $15 million upfront and unspecified, research support and milestones to begin work on new biomarkers and therapeutics for cancer. Bristol-Myers is looking to the gut for new insights into the way the microbiome influences resistance and response to immunotherapies, like its blockbuster checkpoint Opdivo. “Enterome’s focus on target identification and validation along with their significant experience in microbiome research can help to advance our goal to improve outcomes for patients treated with immunotherapies,” said Carl Decicco, head of discovery at Bristol-Myers Squibb.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.